The first two drugs that Gileads has been approved for, the glioma drug rivastigmine and the colorectal cancer drug dutasteride, are currently being tested in patients with colorene and gliomas.
They were also found to be safe in patients who have had an earlier diagnosis of the disease, according to the company.
The company is expected to announce the results of the testing next week, with the first two products expected to be on the market in a year’s time.
Read moreWhat we knowGilead is currently testing a second drug, called rivacoxib, for patients with metastatic gliomyelitis, a condition in which the cancer cells invade the body’s blood vessels and spread to other parts of the body.
This treatment is already approved for some patients.
The drug is expected for a later date.
Gileads is also testing a treatment for glucometabolism, a disease that affects around 10 million people worldwide.
The treatment targets a protein that plays a crucial role in making glucose.
If the protein is deficient, it can cause the cells to die.
The company is working on a new treatment for the disease.
It is being tested by researchers in Israel, the United States and Germany.
The first two are known as the “vitabiggan” and the “dutasterider” drugs.
The “duvacox” drug is being developed for the treatment of gliocytic leukemia, a rare, aggressive form of the cancer that affects 1.5 million people in the United Kingdom.
This is the first time Gileaders drug has been tested in people with this disease.
The first phase of the drug, a “triple-blind” trial, began in April.
Read the rest of this article